Overview: Biofrontera AG reported Q3 2024 revenue of USD 9.01 million, up 14.96% QoQ and 1.50% YoY, supported by its dermatology product portfolio (Ameluz, BF-RhodoLED) and improving utilization in key markets. Despite the revenue uptick, the company posted a net loss of USD 5.67 million and an EBITDA loss of USD 5.35 million, driven primarily by sustained operating expenses and ongoing investments in commercialization and R&D. The quarterly results also reflect continued cash burn, with net cash used in operating activities of USD 1.21 million and a net cash decrease of USD 1.51 million for the period, ending with USD 3.07 million in cash and cash equivalents. On the balance sheet, Biofrontera carries a modest equity base (USD 5.53 million) and a net debt position of USD -1.88 million, highlighting a fragile liquidity runway that will hinge on successful product monetization and potential pipeline milestones.